and further. Don't get me wrong as I have highlighted in the last line, it is a great story but one that should not be exaggerated.
"In a recent prospective clinical trial, using GM-CSF, abscopal responses occurred in 11 of 41 accrued patients (8). In another study, Grimaldi et al. reported a 52% abscopal response rate among 21 patients with melanoma who progressed after receiving the immunoadjuvant ipilimumab (anti-CTLA4) during palliative radiotherapy (23). Noteworthy, in this report, was an indication that a local response was a prerequisite for priming an abscopal effect. Furthermore, a 2015 review article by Reynders et al. (24) described 23 case reports and 13 preclinical studies on the abscopal effect. They observed that 11 of the 13 preclinical studies used immunoadjuvants to achieve an abscopal response. Altogether, these findings strongly suggest that a combination of radiotherapy with immunoadjuvants improves abscopal response rates compared to using radiotherapy alone." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388832/
- Forums
- ASX - By Stock
- Interesting times
and further. Don't get me wrong as I have highlighted in the...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 52445 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.0¢ | 46575 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 620344 | 0.110 |
1 | 9523 | 0.105 |
5 | 149890 | 0.100 |
1 | 25357 | 0.098 |
2 | 176978 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.120 | 106914 | 1 |
0.125 | 128094 | 1 |
0.130 | 166171 | 3 |
0.135 | 199760 | 1 |
0.140 | 230213 | 8 |
Last trade - 12.47pm 27/11/2024 (20 minute delay) ? |
NOX (ASX) Chart |
Day chart unavailable